Aicuris' Pritelivir Meets Primary Endpoint in Phase 3 Trial for Refractory Herpes Simplex Virus in Immunocompromised Patients

Aicuris Anti-infective Cures AG announced positive results from its Phase 3 trial (PRIOH-1) of pritelivir for treating refractory Herpes Simplex Virus...

Empowering Life Sciences with
Advanced AI Solutions.

Book A Demo
HomeKnolsightsContact UsPricingFinancial solutions
One Research Court, Suite 450, Rockville, MD 20850
info@pienomial.com
+91 9876543210
© 2025 Pienomial. All rights reserved
AboutTerms of ServicePrivacy Policy
Home/KnloSights/Clinical Trial Updates/Aicuris' Pritelivir Meets Primary Endpoint in Phase 3 Trial for Refractory Herpes Simplex Virus in Immunocompromised Patients